Latest Hypnotics Stories
DALLAS, September 20, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Insomnia Market Forecast Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33201-insomnia-market-forecast.html Search More Then 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Datamonitor Research Reports at http://www.reportsandreports.com/Publishers/datamonitor/ The availability of...
TEL AVIV, Israel, July 5, 2010 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.Neurim.com) confirmed today that the European Commission (EC) has approved a change in treatment duration with Circadin from 3 to 13 weeks (3 months).
When seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity.
Individuals with chronic insomnia have an elevated risk of death.
WASHINGTON, April 27 /PRNewswire-USNewswire/ -- AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration (FDA), the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team (HEAT) announced today.
WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for treatment resistant depression therapy, AstraZeneca/Targacept's TC-5214 will earn Decision Resources' proprietary clinical gold standard status in 2013 (following its approval that year) and through 2018.
NORTH KINGSTOWN, R.I., April 15 /PRNewswire/ -- Unintentional poisoning deaths have dramatically increased over the last decade to become the second leading cause of injury deaths in the United States.
MORRISTOWN, N.J., March 17 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets.
FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S.
The UNâ€™s top global drug regulator said on Wednesday that more people are turning to prescription drug abuse than cocaine, heroin and ecstasy combined.